Detalhe da pesquisa
1.
ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers.
Mol Cancer Ther
; 19(9): 1833-1843, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32669315